Loading organizations...
ArcoScreen is a Lausanne, Switzerland-based biotechnology enterprise that develops a microfluidic drug discovery platform specifically designed to screen compounds targeting G protein-coupled receptors directly on primary patient cells. The firm provides pharmaceutical companies and life sciences research organizations with proprietary assays, including its SynScreen technology, to identify drug modes of action in a single test while reducing the industry's reliance on animal testing. Operating as an official spin-off from the research institute EPFL, the business generates revenue through a combination of platform-as-a-service offerings and fee-for-service technological solutions for early-stage drug developers. To finance the industrialization of its screening kits, the four-employee organization secured a CHF 1.2 million seed funding round led by Hemex, alongside a CHF 150,000 allocation from Venture Kick. ArcoScreen was officially founded in 2021 by co-founders Margaux Duchamp and Thamani Dahoun.
ArcoScreen has raised $100K across 1 funding round.
ArcoScreen has raised $100K in total across 1 funding round.
ArcoScreen has raised $100K across 1 funding round. Most recently, it raised $100K Seed in October 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 12, 2022 | $100K Seed | Foundation For Technological Innovation | — | Announced |
ArcoScreen has raised $100K in total across 1 funding round.
ArcoScreen's investors include Foundation for Technological Innovation.
